Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Sandoz, STADA, and Samsung Bioepis Report Strong Earnings From Biosimilars

June 10th 2025

By Skylar Jeremias

Article

Leading biosimilar companies Sandoz, STADA Arzneimittel, and Samsung Bioepis report impressive Q1 2025 growth, driven by strong denosumab biosimilars and expanding portfolios.

Boosting Biosimilar Use in Osteoporosis: Why HCP Education Matters

June 9th 2025

By Skylar Jeremias

Article

The biosimilar industry faces awareness challenges among health care professionals (HCPs), which must be addressed to increase cost savings and patient access to treatments.

5 Key Takeaways From the "Escaping the Void" Video Podcast

June 8th 2025

By Skylar Jeremias

Article

Indian Study Finds Comparable Outcomes Between Reference, Biosimilar Bevacizumab in CRC

June 7th 2025

By Deana Ferreri, PhD

Article

Real-world study reveals comparable effectiveness of bevacizumab biosimilars and Avastin in metastatic colorectal cancer (CRC), boosting clinician confidence.

The Top 5 Biosimilar Articles for the Week of June 2

June 6th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of June 2, 2025.

Infliximab Biosimilar Switch Due to Flare Risk: Monitoring Patients Is Crucial for Pharmacists

June 5th 2025

By Cameron Santoro

Article

Switching from reference infliximab to biosimilars (infliximab-abda and infliximab-dyyb) for rheumatic diseases may lead to treatment delays and a higher risk of disease flares, particularly when the switch is mandated by insurance.

Billions in Health Care Savings Realized Through Early Generic, Biosimilar Settlements

June 4th 2025

By Skylar Jeremias

Article

Patent settlements accelerate the entry of generics and biosimilars, saving the health care system $422.9 billion and enhancing drug accessibility.

FDA-Approved SB16 Biosimilar Demonstrates Equivalence to Prolia

June 3rd 2025

By Skylar Jeremias

Article

New research confirms denosumab biosimilar SB16 matches Prolia in efficacy, offering a cost-effective treatment option for postmenopausal osteoporosis.

Wyost and Jubbonti Launch as First Denosumab Biosimilars in the US

June 2nd 2025

By Skylar Jeremias

Article

Denosumab biosimilars Wyost and Jubbonti launch in the US, enhancing access to affordable treatments for osteoporosis and cancer-related skeletal events.

BioRationality: The Urgency of Removing Clinical Efficacy Studies

June 2nd 2025

By Sarfaraz K. Niazi, PhD

Article

Biosimilar associations advocate for lower development costs and streamlined regulations to enhance patient access to affordable biosimilars.